Concepedia

Delvys Rodríguez‐Abreu

DR

Statistics

Publications

131

Citations

43.2K

H-Index

53

Active since

2006

Affiliations

Hospital Universitario Insular de Gran Canaria(Current)

Universidad de Las Palmas de Gran Canaria

Merck & Co., Inc., Rahway, NJ, USA (United States)

Institut Català d'Oncologia

Hospital Universitario Fundación Jiménez Díaz

Delvys Rodríguez‐Abreu is an author at Hospital Universitario Insular de Gran Canaria specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2006–2025

131

Publications

131

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

, , +16

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

, , +12

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

, , +16

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2019 · 1.7K citations · Full text

, , +17

1–5 of 131